Intravenous Immunoglobulins in Dermatology PDF Download

Author: Stephen Jolles
Publisher: CRC Press
ISBN: 9781841841366
Category : Medical
Languages : en
Pages : 168

View

Book Description
This is the first book to bring together the developments in this area. With full colour throughout, each chapter focuses on clinical differentiation and pathophysiology and provides key laboratory and clinical observations. In addition, there is a brief summary of current treatment options.

Author: Hans U. Lutz
Publisher: Springer Science & Business Media
ISBN: 1461434610
Category : Medical
Languages : en
Pages : 285

View

Book Description
This volume illustrates the functional properties of NAbs. Authors from pioneering groups report in their chapters on the tissue homeostatic, tissue regenerating and regulatory properties of NAbs and NAbs in pooled human IgG. Scientists interested in the regulation and modulation of components of the immune system found a whole variety of NAbs to cytokines with regulatory and protective functions and NAbs that modulate, e.g., dendritic cells, regulatory T cells, B cells and granulocytes. Considering the large plasma pools and initial difficulties in preparing IVIG that does not induce adverse effects upon infusion into recipients, this volume ends with a historical chapter on how pooled human plasma was fractionated and the IgG component pretreated for a safe intravenous application.

Author: Isabella Quinti
Publisher: Frontiers Media SA
ISBN: 2889197034
Category : Immunologic diseases. Allergy
Languages : en
Pages : 126

View

Book Description
In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-saving treatment in patients with PID. The rise of new indications for further different clinical conditions resulted in a steady increase in demand for immunoglobulins. Currently the consumption of immunoglobulin for PID represents a small fraction of the market. In the recent past we have been observing: 1) An increase in the demand for plasma and in the consequent need to increase the number of donors; 2) Changes in methods to improve IgG recovery and to increase productivity as a response to growing clinical demand; 3) Introduction of immunoglobulin treatments with higher concentration; 4) Changes in the timing of administration with an increase in the rate of infusion; 5) Introduction of immunoglobulin treatment administered subcutaneously mainly confined initially to patients with PID and later extended to other clinical indications which often require higher volumes of infusion. Doctors following patients with PID were initially alarmed only to a possible risk of shortage. More relevant and less discussed appear the possible consequences of: 1) the risk of an improper transfer of information on treatments from a clinical indication to another. In particular, the idea of a mere replacement function in patients with PID might possibly be borrowed from the model of other clinical conditions requiring a replacement such as haemophilia. In PID, immunoglobulin treatment instead is obviously replacing a missing feature. However, other immune alterations are responsible for the large number of PID-associated diseases including inflammatory manifestations and tumors, common causes of morbidity and mortality. The immunomodulatory effects of immunoglobulin administered at replacement dosages on multiple cells and immune system functions are still largely to be checked in in vitro studies and in vivo. 2) the changes in the immunoglobulin production and schedules of administration. These should have been assessed in studies of drug surveillance, necessary in order to evaluate on large numbers of what it is initially reported on patients enrolled in the pivotal clinical trials, usually in the absence of most of the main disease-associated clinical conditions affecting pharmacokinetics, efficacy and tolerability. Severe side effects are now more frequently reported. This requires surveillance studies in order to verify the tolerability. Nowadays, personalized health research presents methodologic challenges, since emphasis is placed on the individual response rather than on the population. Even within a universally accepted indication, such as in PID, the identification of prognostic markers should guide the therapeutic intervention. 3) the risk of a decrease in the surveillance and monitoring of PID-associated clinical conditions. In fact, self- administration of immunoglobulins administered subcutaneously increased the independence of a number of patients. On the other hand, it led to the reduction in the number of contacts between specialized centers and patients who often require a close monitoring of disease-associated conditions. A wide debate between experts is necessary to afford the new challenge on immunoglobulin usage.

Author: M.D. Kazatchkine
Publisher: CRC Press
ISBN: 9781850706489
Category : Immune response
Languages : en
Pages : 140

View

Book Description
This is a high-level clinical reference text on new developments in therapeutic immunomodulation. It describes the mechanisms of action and clinical use of intravenous immunoglobulin (IVIg), including its effectiveness in clinical conditions. The book also contains three chapters on the safety of IVIg, an overview chapter on IVIg therapy today and tomorrow, and a selected bibliography compiled primarily for practicing physicians. The contributing authors are IVIg experts from the USA, UK, Europe, and Australia.

Author: Alan H. Lazarus
Publisher: A A B B Press
ISBN: 9781563953040
Category : Immunoglobulins
Languages : en
Pages : 279

View

Book Description
Simply put, this text contains all the information you need most about intravenous immunoglobulin (IVIG) products and their use in clinical practice. This collaboration of international experts has resulted in the most comprehensive and up-to-date resource available in an area of transfusion medicine that is rapidly growing. Contents address not only IVIG and anti-D, but also hyperimmune immunoglobulins and therapeutic monoclonal immunoglobulins.

Author: Mark Ballow
Publisher: Springer Science & Business Media
ISBN: 1461204178
Category : Medical
Languages : en
Pages : 155

View

Book Description
It has been little more than a century since Emil von Behring and his colleagues (1890) showed that the blood of tetanus-immune rabbits contained a factor that could be transferred to nonimmune animals to protect them against tetanus. These observations, together with the work of Paul Ehrlich, started scientists on the long and complex path to our present understanding of the humoral, or B-cell, immune system. These early studies led to Nobel prize awards for von Behring (1901 ) and Ehrlich (1908), each of whom contributed much to our knowledge of the B-cell immune system. In the early 20th century it was recognized that the serum of individuals who had recently suffered an infection contained a protective humoral factor that could be transferred to a nonimmune person, thereafter affording that individual protection against the infectious agent that had caused disease. In 1933 McKhann and Chu reported that a placental extract containing the globulin fraction could modify measles. However, it was not until 1939 that Tiselius and Kabat demonstrated that the antibodies responsible for protection against these infectious disorders resided within the gammaglobulin plasma fraction. In a major step forward, Cohn in 1944 established a method for the fractionation and purification of this plasma gammaglobulin fraction. These procedures, which are based on cold ethanol precipitation of plasma, produce a readily adaptable, large-scale fractionation procedure that is still utilized to this day in the preparation of commercial gammaglobulin.

Author: Terumi Kamisawa
Publisher: Springer
ISBN: 9811045488
Category : Medical
Languages : en
Pages : 141

View

Book Description
This book aims to raise awareness of IgG4-related sclerosing cholangitis among practicing physicians and to equip readers with a sound understanding of the principles of diagnosis and treatment. Clinical, serological, and histopathological features are clearly described and imaging appearances on all relevant modalities are illustrated, covering the bile duct and other involved organs. Differential diagnosis from other diseases, including primary sclerosing cholangitis and cholangiocarcinoma, is precisely explained. Information is then presented on all significant current and emerging therapeutic strategies, including steroids, immunosuppressive drugs, and rituximab. Finally, attention is drawn to significant prognostic features. While IgG4-related sclerosing cholangitis is now a widely acknowledged condition, most practitioners are still liable to misdiagnose it owing to a lack of familiarity with its presenting features. This book should help to rectify the situation and will be an asset for all who may encounter the disease in clinical practice.

Author: Paul Imbach
Publisher: Springer
ISBN: 3319680382
Category : Medical
Languages : en
Pages : 361

View

Book Description
This practical manual, written by well-known experts, reviews current indications for the use of IgG concentrates and some other modern immunomodulators and provides fundamental information on present-day immunomodulation in patients (and mice). The book opens by tracing the transition from IgG substitution to IgG immunomodulation and providing expert updates on immunomodulatory indications in autoimmune and inflammatory disorders, including hematologic, neurologic, dermatologic, and other diseases. Basic aspects of IgG concentrates, including methods of production, safety, currently available products, and mechanisms of action, are then discussed. An entire chapter is devoted to the different aspects of immunomodulatory IgG treatment in the bleeding disorder immune thrombocytopenia (ITP). Finally, the transition from polyclonal to monoclonal antibody (mAb) treatment is addressed in detail, covering mAb development, methods, mechanisms of action, adverse effects, and more. Particular attention is paid to the example of anti-CD20 (B-cell) antibody.

Author: R. Cervera
Publisher: Elsevier
ISBN: 0080932347
Category : Medical
Languages : en
Pages : 272

View

Book Description
Antiphospholipid syndrome is an autoimmune disease that causes abnormal blood clots. It is now recognized as a major cause of common conditions, including stroke, heart attack, miscarriage, epilepsy and memory loss and as such is gaining recognition in all branches of medicine, from obstetrics to cardiology, from psychiatry to orthopedics. This book provides an overview of our current understanding of this major disease. It includes the latest information on the new pathogenetic mechanisms involved as well as clinical manifestations in both “the thrombotic and “non-thrombotic manifestations of this important disease. Comprehensive review of this major disease Includes information on treatment options available

Author: Lea Hampton Clark
Publisher:
ISBN: 9781702800853
Category :
Languages : en
Pages : 124

View

Book Description
Keeping an immunoglobulin Ig therapy diary can help you understand and manage your immunodeficiency disorder and provide your doctor with important information to assess how well your Ig treatments are working, whether you receive IVIG or SCIG infusion treatments. This antibody therapy journal can help you track your Ig medication, dose, premedications, adverse reactions, recurring infections and any complications you may experience as a result of your immune deficiency. It can assist you and your doctor in determining whether your Ig therapy is working to treat your health condition or whether any new treatments should be considered. Lightweight and convenient size 6 x 9 inches, this yellow sunflowers abstract art medical journal can help you track important information to discuss with your hematologist or immunology specialist when you have a follow-up appointment.